Aquatic Capital Management LLC Grows Holdings in Merck & Co., Inc. $MRK

Aquatic Capital Management LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 114.9% in the third quarter, HoldingsChannel.com reports. The firm owned 545,395 shares of the company’s stock after buying an additional 291,559 shares during the period. Merck & Co., Inc. accounts for approximately 0.8% of Aquatic Capital Management LLC’s portfolio, making the stock its 14th largest holding. Aquatic Capital Management LLC’s holdings in Merck & Co., Inc. were worth $45,775,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the period. Kilter Group LLC purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Bare Financial Services Inc grew its position in Merck & Co., Inc. by 51.9% in the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its stake in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. during the second quarter worth about $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Insider Activity at Merck & Co., Inc.

In related news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at $10,787,865.12. This represents a 31.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

MRK has been the topic of several recent research reports. TD Cowen upped their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Citigroup boosted their price target on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a research report on Thursday, January 8th. Zacks Research cut Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. Finally, Royal Bank Of Canada started coverage on Merck & Co., Inc. in a report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $126.81.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $115.61 on Friday. The company has a market cap of $285.84 billion, a P/E ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. The firm has a fifty day moving average price of $115.26 and a 200 day moving average price of $99.68. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.